#United States #Class Action #San Francisco #Securities Fraud #ADMA Biologics

ADMA Biologics Investors Alert: Lawsuit Filed

Hagens Berman, a national law firm focusing on investor rights, has issued an alert regarding ADMA Biologics, Inc. (NASDAQ: ADMA). Investors may now have a unique opportunity to lead a class action lawsuit following reports of securities fraud tied to the company.

Key Information from the Class Action Lawsuit

The lawsuit pertains to the period from August 9, 2024, to March 25, 2026. Those who have suffered substantial losses during this interval are encouraged to contact the firm. Detailed information about the lawsuit can be found on their website, and the deadline for potential lead plaintiffs is set for August 10, 2026.

Allegations Against ADMA Biologics

The lawsuit alleges that ADMA Biologics engaged in several forms of misconduct that misled investors about the company’s financial health. Specific claims include:

• - The company purportedly participated in a related-party transaction that was not disclosed.
• - Allegations of channel stuffing were made, suggesting the company inflated its revenue artificially to create a more favorable market appearance.
• - It was also claimed that ADMA Biologics lacked adequate internal controls over its financial reporting, leading to situations where statements made by company executives were materially false and misleading.

The Unfolding of the Allegations

The lawsuit maintains that these misstatements were subsequently uncovered through corrective actions which resulted in severe stock price drops, erasing considerable shareholder value. The market reacted negatively to the information, with significant sell-offs experienced on March 24 and 26, 2026. Here’s a brief breakdown of that timeline:

• - March 24, 2026: A report published by Culper Research triggered a market reaction, revealing allegations of channel stuffing and misleading revenue practices. This led to a 16.6% drop in stock price to $11.33, followed by a further decline of 15% the next day, resulting in a combined decrease of 31.6% in just two days.
• - March 26, 2026: Following the negative press, ADMA Biologics issued a press release acknowledging the allegations but stating the company was reviewing them. However, a downgrade from Cantor Fitzgerald compounded the problem, leading to another decline of 13.9% in share price, closing at $8.29.

Investigation by Hagens Berman

Reed Kathrein, the leading attorney for Hagens Berman, has expressed the firm's commitment to investigating the claims reported in the lawsuit. He stated, “We are examining whether ADMA Biologics made false and misleading statements which concealed the truth about its distribution and financial practices.”

What Affected ADMA Investors Should Consider

If you are an investor in ADMA Biologics and have faced significant losses, now is the time to consider your options. Those with knowledge that may aid the firm’s investigation are also urged to step forward. For additional details, or to participate in the potential class action, investors can reach out to Hagens Berman via phone or email. The firm also provides insights into whistleblower programs that could yield financial rewards for those with non-public information about the company.

About Hagens Berman

Hagens Berman is recognized in the realm of complex litigation, particularly advocating for corporate accountability. The firm has successfully represented numerous plaintiffs, including investors, consumers, and workers, and has secured over $2.9 billion in settlements for its clients. Their mission aligns with obtaining justice for individuals harmed by corporate malfeasance.

Investors are encouraged to stay informed about this developing situation and act promptly to safeguard their interests. For more detailed inquiries about the ADMA Biologics case and its implications, visit Hagens Berman’s official site or contact them directly.